

**Sixth EUCAST steering committee meeting
Summary of minutes of meeting in Paris, France, 3 February 2004**

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Fred Goldstein	FG	SFM	France
Dr Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Dr Ingrid Nilsson-Ehle	IN	SRGA	Sweden
Dr Arne Rodloff	AR	DIN	Germany
Dr Claude-James Soussy	C-JS	SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Pavla Urbaskova	PU	EUCAST	Czech Republic
Dr Alkiviadis Vatopoulos	AV	EUCAST	Greece

Apologies

Dr Anders Österlund	AO	SRGA	Sweden
---------------------	----	------	--------

1	Chairman's welcome and report
2	Minutes of meeting of 18 November 2003 were accepted as a correct record.
3	<p>Matters arising from minutes of 2 September 2003 Declarations of interest are being prepared.</p> <p>Steering Committee responses to comments on proposed breakpoints are to be updated.</p> <p>Roles of clinical and epidemiological breakpoints to be clarified on the website.</p> <p>Justification of breakpoints is an important long-term objective.</p>
4	Breakpoints currently on website for comments. Comments should be encouraged. A meeting had been held with Aventis.
5	Cephalosporin/carbapenem/monobactam breakpoints. A list of agents to consider for revision of breakpoints was agreed. Background data are being collected.
6	Finance. The budget for the DG-SANCO grant has been agreed. Funding would cover Steering Committee meetings, two workshops, secretarial help, and website support and development.
7	EUCAST documents. In the future, Discussion Documents would be published on the website only. Definitive Documents would still be published in CMI.
8	<p>EUCAST breakpoints on the website National committee exceptions are to be noted on breakpoint tables and explanations will be in the background information.</p> <p>Following discussion of data it was agreed that proposed moxifloxacin breakpoints for pneumococci would be changed to 1/1 mg/L.</p> <p>Noted procedures through EMEA would require agreement of the pharmaceutical company.</p> <p>Draft document on procedure for setting breakpoints to go on EUCAST website for comment.</p>
9	NCCLS. A report from GK on the NCCLS meeting in January 2004 was discussed.

- | | |
|----|--|
| 10 | CEN. No recent meeting but comments had been received on the draft reference MIC method. |
| 11 | Discussion with AFSSAPS. Prof. B. Schlemmer, representing the French national drug regulatory committee (AFSSAPS), joined the committee for a discussion of how EUCAST might interact with the breakpoint-setting process in France. Prof. Schlemmer concluded that if EUCAST agreed on a breakpoint for an older agent and sound reasons were given why it should be different from the current French breakpoint there would be no problem with changing the French breakpoint at the regulatory level. Noted that in other countries regulatory authorities defer to national expert committees. |
| 12 | EMEA. GK reported on a very positive meeting with EMEA on 15 December 2003 and tabled a copy of the minutes. Noted that EMEA were currently involved with new drugs only.

Procedures co-ordinating EMEA and EUCAST activity are under development. |
| 13 | EUCAST at ECCMID, Prague. There will be the official EUCAST symposium, symposia on testing difficult organisms and antifungal agents and a poster in the ESCMID "website corner". |
| 14 | Any other business
A contribution to ESCMID News will include the tables of proposed breakpoints.
A response to a letter from Bayer will be sent. |
| 15 | Next meeting. 30 May 2004, at ECCMID, Prague. |

Unratified summary of minutes 2 April 2004
Prepared by DB and GK